Clinical Trials Sponsored by Sideris Pharmaceuticals

Total 19540 results

Sideris Pharmaceuticals

Terminated

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

Iron Overload | Beta-Thalassemia

United States, Canada, Lebanon, Thailand, Turkey
Aderis Pharmaceuticals

Completed

Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation

Atrial Fibrillation

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Completed

PRS-343 in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Pieris Pharmaceuticals, Inc.

Active, not recruiting

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

HER2-positive Gastric Cancer

United States, Korea, Republic of
Asieris Pharmaceutical Technologies Co., Ltd.

Completed

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC)

Non-Muscle Invasive Bladder Cancer (NMIBC)

United States
Asieris Pharmaceuticals (AUS) Pty Ltd.

Completed

A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets

Bladder Cancer

Australia
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Solid Tumor

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Vaderis Therapeutics AG

Recruiting

Assess Safety and Efficacy of VAD044 in HHT Patients

Hereditary Hemorrhagic Telangiectasia (HHT)

United States, Spain, France, Belgium, Netherlands, Italy
Hospital Siberia-Serena

Unknown

Rives Technique Versus Lichtenstein Repair for Primary Inguinal Hernia

Primary Inguinal Hernia

Spain
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Effect of SRT2379 on Endotoxin-Induced Inflammation

Sepsis

Netherlands
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers

Diabetes Mellitus, Type 2 | Healthy Volunteer

United Kingdom
Sidero Bioscience, LLC

Completed

BioFe, Medical Food for the Dietary Management of Iron Deficiency

Iron Deficiency

United States
Pieris Australia Pty Ltd

Completed

Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

Healthy

Australia
Pieris Australia Pty Ltd

Completed

Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

Healthy Subjects

Australia
Superficial Siderosis Research Alliance Inc.

Not yet recruiting

Therapeutic Antioxidant Supplementation (TAS-SS21)

Superficial Siderosis
Sirtris, a GSK Company
GlaxoSmithKline

Terminated

A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

Multiple Myeloma

United Kingdom, Denmark
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Diabetes Mellitus, Type 2

Bulgaria, Estonia, Russian Federation, Ukraine, United Kingdom, Hungary, Poland, Romania
Sirtris, a GSK Company

Completed

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation

Sepsis

Netherlands
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases

Neoplasms, Colorectal

United Kingdom
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Diabetes Mellitus, Type 2

United Kingdom
Asieris MediTech (Hong Kong) Co., Ltd.

Active, not recruiting

Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL) (APRICITY)

Cervical Intraepithelial Neoplasia Grade 2/3

China
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Pieris Australia Pty Ltd

Completed

Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Asthma

Australia
Sirtris, a GSK Company
GlaxoSmithKline

Completed

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Psoriasis

United States
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Clinical Study to Assess the Effect of Food and Gender on the Pharmacokinetics of SRT2104 Administered as an Oral Suspension or Capsule Formulation to Normal Healthy Volunteers

Diabetes Mellitus, Type 2

United Kingdom
Sirtris, a GSK Company

Completed

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Psoriasis

United States
Sirtris, a GSK Company
GlaxoSmithKline

Completed

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Colitis, Ulcerative

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
The Cleveland Clinic
STERIS Corporation

Completed

Effect of the Built Operating Room Environment on Patient Outcome

Anxiety

United States
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers

Bladder Cancer

Australia
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands

3

Subscribe